| 產(chǎn)品編號(hào) | bs-4311R |
| 英文名稱 | Rabbit Anti-NR0B2 antibody |
| 中文名稱 | 核受體0相關(guān)蛋白B家族2抗體 |
| 別 名 | NR0B2; NR0B2_HUMAN; Nr0b2a; Nuclear receptor subfamily 0 group B member 2; Nuclear receptor subfamily 0, group B, member 2a; Orphan nuclear receptor SHP; SHP; SHP-1; Shp1; Small heterodimer partner. |
 |
Specific References (4) | bs-4311R has been referenced in 4 publications.
[IF=6.876] Song Guochao. et al. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. CLIN SCI. 2023 Apr;137(7):561-577 WB ; Mouse.
[IF=4.414] Liu Y et al. Fish?oil?alleviates?circadian?bile?composition?dysregulation?in?male?mice?with?NAFLD. J Nutr Biochem.?2019 Apr 4;69:53-62. WB ; Mouse.
[IF=3.628] Jing Zhao. et al. The choleretic role of tauroursodeoxycholic?acid exacerbates alpha-naphthylisothiocyanate?induced cholestatic liver injury through the FXR/BSEP pathway. J APPL TOXICOL. 2023 Feb;: WB ; Mouse.
[IF=2.65] Shu-Yan Gao. et al. iTRAQ Quantitative Proteomic Analysis of Different Expressed Proteins and Signal Pathways in Bakuchiol-Induced Hepatotoxicity. EVID-BASED COMPL ALT. 2022 Sep 19;2022:2928240 WB ; Human.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 染色質(zhì)和核信號(hào) 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Mouse,Rat (predicted: Human,Rabbit,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 28kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human NR0B2: 31-130/257 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
SHP is an orphan nuclear receptor containing the dimerization and ligand-binding domains found in other nuclear receptors, but lacking the conserved DNA binding domain. SHP is specifically expressed in liver and other tissues, including fetal liver and adrenal gland, as well as adult spleen and small intestine. In addition, SHP is highy expressed in the murine macrophage cell line RAW 264.7 but suppressed by oxLDL and 13-HODE, which is a ligand for PPARg. SHP interacts with nuclear receptors, including thyroid receptor, retinoic acid receptors (RAR and RXR) and estrogen receptors (ERa and ERb). SHP functions as a negative regulator of these receptors by at least three mechanisms: inhibition of DNA binding via dimerization, direct antagonism of coactivator function through competition and possibly transrepression via recruitment of putative corepressors. In oxLDL-treated, resting macrophage cells, SHP acts as a transcription coactivator of NFkB, suggesting that SHP is a modulatory component in the regulation of the transcriptional activities of NFkB. Lastly, negative feedback regulation of a hepatic bile acid transporter, NTCP, is controlled by bile acid-activated FXR via induction of SHP to protect the hepatocyte from bile acid-mediated damage in cholestatic conditions. Function: Acts as a negative regulator of receptor-dependent signaling pathways. Specifically inhibits transactivation of the nuclear receptor with whom it interacts. Subunit: Interacts with RARA, RXRA, THRB, NR5A1, NR5A2, NR1I3, PPARA, PPARG and EID1. May also interact with HNF4A (By similarity). Heterodimer; efficient DNA binding requires dimerization with another bHLH protein. Interacts (via N-terminus) with NEUROD1 (via N-terminus an C-terminus). Interacts with ID2. Subcellular Location: Nucleus. Cytoplasm. Note=Colocalizes with NEUROD1 in the nucleus. Tissue Specificity: Liver. Low levels of expression were detected in heart and pancreas. DISEASE: Defects in NR0B2 may be associated with obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. Similarity: Belongs to the nuclear hormone receptor family. NR0 subfamily. SWISS: Q15466 Gene ID: 8431 Database links: Entrez Gene: 8431 Human Omim: 604630 Human SwissProt: Q15466 Human Unigene: 427055 Human |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Rat Kidney tissue lysates
Lane 2: Rat Small intestine tissue lysates
Primary: Anti-NR0B2 (bs-4311R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 28 kDa
Observed band size: 28 kDa
Paraformaldehyde-fixed, paraffin embedded (rat lung); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (NR0B2) Polyclonal Antibody, Unconjugated (bs-4311R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (NR0B2) Polyclonal Antibody, Unconjugated (bs-4311R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Tissue/cell: mouse spleen tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-NROB2 Polyclonal Antibody, Unconjugated(bs-4311R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
